Scientific Articles

Find Articles

The scientific articles listed below are authored by GHIT's product development partners and refer to projects that have been fully or partially funded by GHIT. This growing archive demonstrates our partners' important scientific accomplishments while illustrating the progress of GHIT's investments.
Create Excel File
Year of Publication Diseases Development Stage Intervention Publication Other links Project overview
2022 Malaria Drug Lead Identification Drug

Xie SC, Metcalfe RD, Dunn E, Morton CJ, Huang SC, Puhalovich T, Du Y, Wittlin S, Nie S, Luth MR, Ma L, Kim MS, Pasaje CFA, Kumpornsin K, Giannangelo C, Houghton FJ, Churchyard A, Famodimu MT, Barry DC, Gillett DL, Dey S, Kosasih CC, Newman W, Niles JC, Lee MCS, Baum J, Ottilie S, Winzeler EA, Creek DJ, Williamson N, Parker MW, Brand S, Langston SP, Dick LR, Griffin MDW, Gould AE, Tilley L. Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science. 2022 Jun 3;376(6597):1074-1079. doi: 10.1126/science.abn0611. Epub 2022 Jun 2. PMID: 35653481.

2021 Malaria Drug Lead Optimization Drug

Sharma M, Malhotra N, Yogavel M, Harlos K, Melillo B, Comer E, Gonse A, Parvez S, Mitasev B, Fang FG, Schreiber SL, Sharma A. Structural basis of malaria parasite phenylalanine tRNA-synthetase inhibition by bicyclic azetidines. Nat Commun. 2021 Jan 12;12(1):343. doi: 10.1038/s41467-020-20478-5. PMID: 33436639; PMCID: PMC7803973.

2021 NTD (Leishmaniasis) Drug Hit Identification Drug

Akao Y, Canan S, Cao Y, Condroski K, Engkvist O, Itono S, Kaki R, Kimura C, Kogej T, Nagaoka K, Naito A, Nakai H, Pairaudeau G, Radu C, Roberts I, Shimada M, Shum D, Watanabe N, Xie H, Yonezawa S, Yoshida O, Yoshida R, Mowbray C, Perry B. RSC Medicinal Chemistry 2021. doi: 10.1039/D0MD00353K

2021 Malaria Vaccine Preclinical Development Vaccine

Nicole G Bender, Prachi Khare, Juan Martinez, Rebecca E Tweedell, Vincent O Nyasembe, Borja López-Gutiérrez, Abhai Tripathi, Dustin Miller, Timothy Hamerly, Eric M Vela, Ryan R Davis, Randall F Howard, Sandrine Nsango, Ronald R Cobb, Matthias Harbers, Rhoel R Dinglasan. Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen. NPJ Vaccines. 2021 Apr 6;6(1):49. doi: 10.1038/s41541-021-00309-4. PMID: 33824336.

2021 Malaria Vaccine Preclinical Development Vaccine

Kaci D McCoy, Caroline T Weldon, Rashid Ansumana, Joseph M Lamin, David A Stenger, Sadie J Ryan, Kevin Bardosh, Kathryn H Jacobsen, Rhoel R Dinglasan. Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone. Malar J . 2021 Apr 13;20(1):183. doi: 10.1186/s12936-021-03723-0. PMID: 33849572.

2021 NTD (Schistosomiasis) Diagnostic Concept Development Diagnostic

Mio Tanaka, Anna O Kildemoes, Evans Asena Chadeka, Benard Ngetich Cheruiyot, Miho Sassa, Taeko Moriyasu, Risa Nakamura, Mihoko Kikuchi, Yoshito Fujii, Claudia J de Dood, Paul L A M Corstjens, Satoshi Kaneko, Haruhiko Maruyama, Sammy M Njenga, Remco de Vrueh, Cornelis H Hokke, Shinjiro HamanoPotential of antibody test using Schistosoma mansoni recombinant serpin and RP26 to detect light-intensity infections in endemic areas. Parasitol Int. 2021 Apr 12;102346. doi: 10.1016/j.parint.2021.102346. PMID: 33857597

2021 NTD (Leishmaniasis) Vaccine Preclinical Development Vaccine

Subir Karmakar, Nevien Ismail, Fabiano Oliveira, James Oristian, Wen Wei Zhang, Swarnendu Kaviraj, Kamaleshwar P Singh, Abhishek Mondal, Sushmita Das, Krishna Pandey, Parna Bhattacharya, Greta Volpedo, Sreenivas Gannavaram, Monika Satoskar, Sanika Satoskar, Rajiv M Sastry, Timur Oljuskin, Telly Sepahpour, Claudio Meneses, Shinjiro Hamano, Pradeep Das, Greg Matlashewski, Sanjay Singh, Shaden Kamhawi, Ranadhir Dey, Jesus G Valenzuela, Abhay Satoskar, Hira L Nakhasi. Preclinical validation of a live attenuated dermotropic Leishmania vaccine against vector transmitted fatal visceral leishmaniasis. Commun Biol. 2021 Jul 30;4(1):929. doi: 10.1038/s42003-021-02446-x. PMID: 34330999 PMCID: PMC8324786

2021 NTD (Schistosomiasis) Drug Clinical Phase1 Drug

Muhidin K. Mahende, Eric Huber, Elly Kourany-Lefoll, Ali Ali,Brooke Hayward, Deon Bezuidenhout, Wilhelmina Bagchus, Abdunoor M. Kabanywanyi. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021 Jun 9;15(6):e0007370. doi: 10.1371/journal.pntd.0007370. eCollection 2021 Jun. PMID: 34106922; PMCID: PMC8216518.

2021 NTD (Schistosomiasis) Drug Clinical Phase2 Drug

Xiaoyan Yin, Eliézer K. N’Goran, Mamadou Ouattara, NAD. Aka, Nana R. Diakité, Fidèle K. Bassa, Elly Kourany-Lefoll, Aliona Tappert, Özkan Yalkinoglu, Eric Huber, Deon Bezuidenhout, Wilhelmina M. Bagchus and Brooke Hayward1 on behalf of on behalf of the Pediatric Praziquantel Consortium. Comparison of POC-CCA with Kato-Katz in Diagnosing Schistosoma mansoni Infection in a Pediatric L-Praziquantel Clinical Trial. Front. Trop. Dis, 17 June 2021.

2021 Malaria Drug Lead Identification Drug

Stanley C Xie, Riley D Metcalfe, Hirotake Mizutani, Tanya Puhalovich, Eric Hanssen, Craig J Morton, Yawei Du, Con Dogovski, Shih-Chung Huang, Jeffrey Ciavarri, Paul Hales, Robert J Griffin, Lawrence H Cohen, Bei-Ching Chuang, Sergio Wittlin, Ioanna Deni, Tomas Yeo, Kurt E Ward, Daniel C Barry, Boyin Liu, David L Gillett, Benigno F Crespo-Fernandez, Sabine Ottilie, Nimisha Mittal, Alisje Churchyard, Daniel Ferguson, Anna Caroline C Aguiar, Rafael V C Guido, Jake Baum, Kirsten K Hanson, Elizabeth A Winzeler, Francisco-Javier Gamo, David A Fidock, Delphine Baud, Michael W Parker, Stephen Brand, Lawrence R Dick, Michael D W Griffin, Alexandra E Gould, Leann Tilley. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):e2107213118. doi: 10.1073/pnas.2107213118. PMID: 34548400.

2020 Malaria Vaccine Phase1 Clinical Development Vaccine

Ezoe S, Palacpac NMQ, Tetsutani K, Yamamoto K, Okada K, Taira M, Nishida S, Hirata H, Ogata A, Yamada T, Yagi M, Edula JR, Oishi Y, Tougan T, Ishii KJ, Myoui A, Horii T. First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3). Vaccine. 2020 Oct 27;38(46):7246-7257. doi: 10.1016/j.vaccine.2020.09.056. Epub 2020 Oct 2. PMID: 33012605.

2020 Malaria Vaccine Phase1 Clinical Development Vaccine

Tougan T, Edula JR, Morita M, Takashima E, Honma H, Tsuboi T, Horii T. The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicity. Malar J. 2020 Apr 15;19(1):155. doi: 10.1186/s12936-020-03229-1. PMID: 32295584; PMCID: PMC7161009.

2020 Malaria Vaccine Phase1 Clinical Development Vaccine

Balikagala B, Sakurai-Yatsushiro M, Tachibana SI, Ikeda M, Yamauchi M, Katuro OT, Ntege EH, Sekihara M, Fukuda N, Takahashi N, Yatsushiro S, Mori T, Hirai M, Opio W, Obwoya PS, Anywar DA, Auma MA, Palacpac NMQ, Tsuboi T, Odongo-Aginya EI, Kimura E, Ogwang M, Horii T, Mita T. Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malar J. 2020 Feb 18;19(1):76. doi: 10.1186/s12936-020-03157-0. PMID: 32070358; PMCID: PMC7026951.

2020 Malaria Vaccine Antigen Identification Vaccine

Nagaoka H, Kanoi BN, Ntege EH, Aoki M, Fukushima A, Tsuboi T, Takashima E. Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Sci Rep. 2020 Apr 20;10(1):6573. doi: 10.1038/s41598-020-63611-6. PMID: 32313230; PMCID: PMC7171142.

2020 Malaria Diagnostic Technical Feasibility Diagnostic

Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, Obadia T, Robinson LJ, Matsuura F, Liu ZSJ, Li-Wai-Suen CSN, Tham WH, Healer J, Huon C, Chitnis CE, Nguitragool W, Monteiro W, Proietti C, Doolan DL, Siqueira AM, Ding XC, Gonzalez IJ, Kazura J, Lacerda M, Sattabongkot J, Tsuboi T, Mueller I. Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nat Med. 2020 May;26(5):741-749. doi: 10.1038/s41591-020-0841-4. Epub 2020 May 11. PMID: 32405064.

2020 NTD (Leishmaniasis) Vaccine Preclinical Development Vaccine

Zhang WW, Karmakar S, Gannavaram S, Dey R, Lypaczewski P, Ismail N, Siddiqui A, Simonyan V, Oliveira F, Coutinho-Abreu IV, DeSouza-Vieira T, Meneses C, Oristian J, Serafim TD, Musa A, Nakamura R, Saljoughian N, Volpedo G, Satoskar M, Satoskar S, Dagur PK, McCoy JP, Kamhawi S, Valenzuela JG, Hamano S, Satoskar AR, Matlashewski G, Nakhasi HL. A second generation leishmanization vaccine with a markerless attenuated Leishmania major strain using CRISPR gene editing. Nat Commun. 2020 Jul 10;11(1):3461. doi: 10.1038/s41467-020-17154-z. PMID: 32651371; PMCID: PMC7351751.

2020 NTD (Leishmaniasis) Drug Preclinical development Drug

Van den Kerkhof M, Mabille D, Hendrickx S, Leprohon P, Mowbray CE, Braillard S, Ouellette M, Maes L, Caljon G. Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00152-20. doi: 10.1128/AAC.00152-20. PMID: 32601168; PMCID: PMC7449183.

2020 NTD (Leishmaniasis) Drug Preclinical development Drug

Thacker SG, McWilliams IL, Bonnet B, Halie L, Beaucage S, Rachuri S, Dey R, Duncan R, Modabber F, Robinson S, Bilbe G, Arana B, Verthelyi D. CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis. PLoS Negl Trop Dis. 2020 Feb 28;14(2):e0008050. doi: 10.1371/journal.pntd.0008050. PMID: 32109251; PMCID: PMC7075640.

2020 Tuberculosis Vaccine Phase2 Clinical Development Vaccine

Munseri P, Said J, Amour M, Magohe A, Matee M, Rees CA, Mackenzie T, Tvaroha S, Bailey-Kellogg C, Maro I, Wieland-Alter W, Adams LV, Horsburgh CR, Nakamura K, Arbeit RD, Pallangyo K, von Reyn CF. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine. 2020 Oct 27;38(46):7239-7245. doi: 10.1016/j.vaccine.2020.09.055. Epub 2020 Sep 29. PMID: 33004239.

2020 Tuberculosis Diagnostic Product Validation Diagnostic

Broger T, Nicol MP, Székely R, Bjerrum S, Sossen B, Schutz C, Opintan JA, Johansen IS, Mitarai S, Chikamatsu K, Kerkhoff AD, Macé A, Ongarello S, Meintjes G, Denkinger CM, Schumacher SG. Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data. PLoS Med. 2020 May 1;17(5):e1003113. doi: 10.1371/journal.pmed.1003113. PMID: 32357197; PMCID: PMC7194366.

2020 Tuberculosis Drug Lead Optimization Drug

Michalska K, Chang C, Maltseva NI, Jedrzejczak R, Robertson GT, Gusovsky F, McCarren P, Schreiber SL, Nag PP, Joachimiak A. Allosteric inhibitors of Mycobacterium tuberculosis tryptophan synthase. Protein Sci. 2020 Mar;29(3):779-788. doi: 10.1002/pro.3825. Epub 2020 Jan 20. PMID: 31930594; PMCID: PMC7020977.

2020 Malaria Vaccine Antigen Identification Vaccine

Huang WC, Deng B, Mabrouk MT, Seffouh A, Ortega J, Long C, Miura K, Wu Y, Lovell JF. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose. Malar J. 2020 Aug 28;19(1):309. doi: 10.1186/s12936-020-03368-5. PMID: 32859199; PMCID: PMC7453371.

2020 Malaria Vaccine Antigen Identification Vaccine

Huang WC, Deng B, Seffouh A, Ortega J, Long CA, Suresh RV, He X, Miura K, Lee SM, Wu Y, Lovell JF. Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment. NPJ Vaccines. 2020 Mar 18;5:23. doi: 10.1038/s41541-020-0173-x. PMID: 32218995; PMCID: PMC7080793.

2020 Malaria Vaccine Antigen Identification Vaccine

Mabrouk MT, Huang WC, Deng B, Li-Purcell N, Seffouh A, Ortega J, Ekin Atilla-Gokcumen G, Long CA, Miura K, Lovell JF. Lyophilized, antigen-bound liposomes with reduced MPLA and enhanced thermostability. Int J Pharm. 2020 Sep 2;589:119843. doi: 10.1016/j.ijpharm.2020.119843. Epub ahead of print. PMID: 32890653.

2020 NTD (Dengue) Vaccine Preclinical Development Vaccine

Yoshimura M, Shinmura Y, Takagi S, Kameyama K, Sonoda K, Koide F, Yoksan S, Kimachi K. Well-balanced immune response and protective efficacy induced by a single dose of live attenuated tetravalent dengue vaccine (KD-382) in monkeys. Heliyon. 2020 Jul 28;6(7):e04506. doi: 10.1016/j.heliyon.2020.e04506. PMID: 32760828; PMCID: PMC7393427.

2019 NTD (Schistosomiasis) Drug Clinical Phase1 Drug

Muhidin K Mahende, Eric Huber, Elly Kourany-Lefoll, Ali Ali, Brooke Hayward, Deon Bezuidenhout, Wilhelmina Bagchus, Abdunoor M Kabanywanyi, On behalf of the Pediatric Praziquantel Consortium. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: a randomized, single-blind, crossover study. bioRxiv 605170; doi: https://doi.org/10.1101/605170

2019 Malaria Drug Clinical Phase1 Drug

McCarthy JS, Rückle T, Elliott SL, Ballard E, Collins KA, Marquart L, Griffin P, Chalon S, Möhrle JJ. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01371-19. doi: 10.1128/AAC.01371-19. PMID: 31685476; PMCID: PMC7187626.

2019 Malaria Diagnostic Product Validation Diagnostic

Yamamoto T, Yatsushiro S, Hashimoto M, Kajimoto K, Ido Y, Abe K, Sofue Y, Nogami T, Hayashi T, Nagatomi K, Minakawa N, Oka H, Mita T, Kataoka M. Development of a highly sensitive, quantitative, and rapid detection system for Plasmodium falciparum-infected red blood cells using a fluorescent blue-ray optical system. Biosens Bioelectron. 2019 May 1;132:375-381. doi: 10.1016/j.bios.2019.02.064. Epub 2019 Mar 7. PMID: 30901727.

2019 Malaria Vaccine Antigen Identification Vaccine

Tachibana M, Miura K, Takashima E, Morita M, Nagaoka H, Zhou L, Long CA, Richter King C, Torii M, Tsuboi T, Ishino T. Identification of domains within Pfs230 that elicit transmission blocking antibody responses. Vaccine. 2019 Mar 22;37(13):1799-1806. doi: 10.1016/j.vaccine.2019.02.021. Epub 2019 Feb 26. PMID: 30824357; PMCID: PMC6708081.

2019 NTD (Schistosomiasis) Drug Clinical Phase2 Drug

N'Goran E, David Aka NA, Ouattara M, Huber E, Bezuidenhout D, Kourany-Lefoll E; Pediatric Praziquantel Consortium. Challenges and Lessons From Conducting A Paediatric Clinical Trial in Sub-Saharan Africa: The Case of the Praziquantel Oral Dispersible Tablets Phase II Study in Côte d'Ivoire. Adv Parasitol. 2019;103:75-89. doi: 10.1016/bs.apar.2018.09.002. Epub 2018 Oct 22. PMID: 30878059.

2019 Tuberculosis Diagnostic Product Validation Diagnostic

Broger T, Sossen B, du Toit E, Kerkhoff AD, Schutz C, Ivanova Reipold E, Ward A, Barr DA, Macé A, Trollip A, Burton R, Ongarello S, Pinter A, Lowary TL, Boehme C, Nicol MP, Meintjes G, Denkinger CM. Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study. Lancet Infect Dis. 2019 Aug;19(8):852-861. doi: 10.1016/S1473-3099(19)30001-5. Epub 2019 May 30. PMID: 31155318; PMCID: PMC6656794.

2019 Malaria Drug Lead Identification Drug

Xie SC, Dick LR, Gould A, Brand S, Tilley L. The proteasome as a target for protozoan parasites. Expert Opin Ther Targets. 2019 Nov;23(11):903-914. doi: 10.1080/14728222.2019.1685981. Epub 2019 Nov 4. PMID: 31679410.

2018 NTD (Schistosomiasis) Drug Clinical Phase1 Drug

Bonate PL, Wang T, Passier P, Bagchus W, Burt H, Lüpfert C, Abla N, Kovac J, Keiser J. Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):747-762. doi: 10.1007/s10928-018-9601-1. Epub 2018 Sep 14. PMID: 30218416; PMCID: PMC6182730.

2018 Malaria Vaccine Phase1 Clinical Development Vaccine

Ikeda M, Kaneko M, Tachibana SI, Balikagala B, Sakurai-Yatsushiro M, Yatsushiro S, Takahashi N, Yamauchi M, Sekihara M, Hashimoto M, Katuro OT, Olia A, Obwoya PS, Auma MA, Anywar DA, Odongo-Aginya EI, Okello-Onen J, Hirai M, Ohashi J, Palacpac NMQ, Kataoka M, Tsuboi T, Kimura E, Horii T, Mita T. Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014-2016. Emerg Infect Dis. 2018 Apr;24(4):718-726. doi: 10.3201/eid2404.170141. PMID: 29553316; PMCID: PMC5875287.

2018 Malaria Vaccine Phase1 Clinical Development Vaccine

Tougan T, Edula JR, Takashima E, Morita M, Shinohara M, Shinohara A, Tsuboi T, Horii T. Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Sci Rep. 2018 Mar 22;8(1):5052. doi: 10.1038/s41598-018-23194-9. PMID: 29567995; PMCID: PMC5864917.

2018 Malaria Drug Lead Identification Drug

Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould AE, Hales P, Seager BA, Charron CL, Bruzzese F, Yang X, Zhao X, Huang SC, Hutton CA, Burrows JN, Winzeler EA, Avery VM, Dick LR, Tilley L. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome. J Med Chem. 2018 Nov 21;61(22):10053-10066. doi: 10.1021/acs.jmedchem.8b01161. Epub 2018 Nov 7. PMID: 30373366; PMCID: PMC6257627.

2018 Malaria Drug Lead Identification Drug

Bridgford JL, Xie SC, Cobbold SA, Pasaje CFA, Herrmann S, Yang T, Gillett DL, Dick LR, Ralph SA, Dogovski C, Spillman NJ, Tilley L. Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome. Nat Commun. 2018 Sep 18;9(1):3801. doi: 10.1038/s41467-018-06221-1. PMID: 30228310; PMCID: PMC6143634.

2018 NTD (Leishmaniasis) Drug Lead Optimization Drug

Van den Kerkhof M, Mabille D, Chatelain E, Mowbray CE, Braillard S, Hendrickx S, Maes L, Caljon G. In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):81-86. doi: 10.1016/j.ijpddr.2018.01.006. Epub 2018 Jan 31. PMID: 29425734; PMCID: PMC6114106.

2018 NTD (Schistosomiasis) Drug Clinical Phase1 Drug

Bonate PL, Wang T, Passier P, Bagchus W, Burt H, Lüpfert C, Abla N, Kovac J, Keiser J. Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. J Pharmacokinet Pharmacodyn. 2018 Oct;45(5):747-762. doi: 10.1007/s10928-018-9601-1. Epub 2018 Sep 14. PMID: 30218416; PMCID: PMC6182730.

2018 NTD (Schistosomiasis) Drug Clinical Phase1 Drug

Bagchus WM, Bezuidenhout D, Harrison-Moench E, Kourany-Lefoll E, Wolna P, Yalkinoglu O. Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: Two Phase I Studies. Clin Transl Sci. 2019 Jan;12(1):66-76. doi: 10.1111/cts.12601. Epub 2018 Dec 21. PMID: 30536632; PMCID: PMC6342245.

2017 Malaria Vaccine Phase1 Clinical Development Vaccine

Balikagala B, Mita T, Ikeda M, Sakurai M, Yatsushiro S, Takahashi N, Tachibana SI, Auma M, Ntege EH, Ito D, Takashima E, Palacpac NM, Egwang TG, Onen JO, Kataoka M, Kimura E, Horii T, Tsuboi T. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda. Malar J. 2017 Jan 9;16(1):23. doi: 10.1186/s12936-016-1663-1. PMID: 28068997; PMCID: PMC5223472.

2017 Malaria Vaccine Phase1 Clinical Development Vaccine

Odongo-Aginya EI, Olia A, Luwa KJ, Nagayasu E, Auma AM, Egitat G, Mwesigwa G, Ogino Y, Kimura E, Horii T. Wuchereria bancrofti infection at four primary schools and surrounding communities with no previous blood surveys in northern Uganda: the prevalence after mass drug administrations and a report on suspected non-filarial endemic elephantiasis. Trop Med Health. 2017 Aug 15;45:20. doi: 10.1186/s41182-017-0060-y. Erratum in: Trop Med Health. 2017 Sep 20;45:28. PMID: 28814926; PMCID: PMC5556395.

2017 Malaria Drug Clinical Phase1 Drug

McCarthy JS, Lotharius J, Rückle T, Chalon S, Phillips MA, Elliott S, Sekuloski S, Griffin P, Ng CL, Fidock DA, Marquart L, Williams NS, Gobeau N, Bebrevska L, Rosario M, Marsh K, Möhrle JJ. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis. 2017 Jun;17(6):626-635. doi: 10.1016/S1473-3099(17)30171-8. Epub 2017 Mar 28. PMID: 28363636; PMCID: PMC5446412.

2017 Malaria Drug Clinical Phase1 Drug

Sulyok M, Rückle T, Roth A, Mürbeth RE, Chalon S, Kerr N, Samec SS, Gobeau N, Calle CL, Ibáñez J, Sulyok Z, Held J, Gebru T, Granados P, Brückner S, Nguetse C, Mengue J, Lalremruata A, Sim BKL, Hoffman SL, Möhrle JJ, Kremsner PG, Mordmüller B. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017 Jun;17(6):636-644. doi: 10.1016/S1473-3099(17)30139-1. Epub 2017 Mar 28. Erratum in: Lancet Infect Dis. 2017 Jun;17(6):576. PMID: 28363637; PMCID: PMC5446410.

2017 Malaria Drug Lead Optimization Drug

Maetani M, Zoller J, Melillo B, Verho O, Kato N, Pu J, Comer E, Schreiber SL. Synthesis of a Bicyclic Azetidine with In Vivo Antimalarial Activity Enabled by Stereospecific, Directed C(sp3)-H Arylation. J Am Chem Soc. 2017 Aug 16;139(32):11300-11306. doi: 10.1021/jacs.7b06994. Epub 2017 Aug 7. PMID: 28732448; PMCID: PMC5561537.

2017 NTD (Dengue) Vaccine Preclinical Development Vaccine

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. J Virol. 2017 Nov 14;91(23):e01181-17. doi: 10.1128/JVI.01181-17. PMID: 28956764; PMCID: PMC5686733.

2017 NTD (Dengue) Drug Preclinical development Drug

Meihui Xu, Roland Zuest, Sumathy Velumani, Farhana Tukijan, Ying Xiu Toh, Ramapraba Appanna, Ern Yu Tan, Daniela Cerny, Paul MacAry, Cheng-I Wang, Katja Fink. A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus. NPJ Vaccines. 2017 Jan 23;2:2. doi: 10.1038/s41541-016-0003-3. eCollection 2017 PMID: 29263863; PMCID: PMC5627287

2017 NTD (Dengue) Drug Preclinical development Drug

Yiu-Wing Kam, Cheryl Yi-Pin Lee, Teck-Hui Teo, Shanshan W Howland, Siti Naqiah Amrun, Fok-Moon Lum, Peter See, Nicholas Qing-Rong Kng, Roland G Huber, Mei-Hui Xu, Heng-Liang Tan, Andre Choo, Sebastian Maurer-Stroh, Florent Ginhoux, Katja Fink, Cheng-I Wang, Lisa Fp Ng, Laurent Rénia. Cross-reactive dengue human monoclonal antibody prevents severe pathologies and death from Zika virus infections. JCI Insight. 2017 Apr 20;2(8):e92428. doi: 10.1172/jci.insight.92428. PMID: 28422757; PMCID: PMC5396524

2016 Malaria Vaccine Phase1 Clinical Development Vaccine

Yagi M, Palacpac NM, Ito K, Oishi Y, Itagaki S, Balikagala B, Ntege EH, Yeka A, Kanoi BN, Katuro O, Shirai H, Fukushima W, Hirota Y, Egwang TG, Horii T. Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. Sci Rep. 2016 Oct 5;6:34363. doi: 10.1038/srep34363. PMID: 27703240; PMCID: PMC5050508.

2016 Malaria Vaccine Phase1 Clinical Development Vaccine

Tougan T, Ito K, Palacpac NM, Egwang TG, Horii T. Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles. Parasitol Int. 2016 Oct;65(5 Pt A):455-8. doi: 10.1016/j.parint.2016.06.012. Epub 2016 Jun 23. PMID: 27343834.

2016 Malaria Vaccine Phase1 Clinical Development Vaccine

Yatsushiro S, Yamamoto T, Yamamura S, Abe K, Obana E, Nogami T, Hayashi T, Sesei T, Oka H, Okello-Onen J, Odongo-Aginya EI, Alai MA, Olia A, Anywar D, Sakurai M, Palacpac NM, Mita T, Horii T, Baba Y, Kataoka M. Application of a cell microarray chip system for accurate, highly sensitive, and rapid diagnosis for malaria in Uganda. Sci Rep. 2016 Jul 22;6:30136. doi: 10.1038/srep30136. PMID: 27445125; PMCID: PMC4995311.

2016 Malaria Vaccine Phase1 Clinical Development Vaccine

Ntege EH, Arisue N, Ito D, Hasegawa T, Palacpac NMQ, Egwang TG, Horii T, Takashima E, Tsuboi T. Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Vaccine. 2016 Nov 4;34(46):5612-5622. doi: 10.1016/j.vaccine.2016.09.028. Epub 2016 Sep 28. PMID: 27692771.

2016 Malaria Drug Lead Optimization Drug

Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, Bastien J, Brancucci NM, Bittker JA, Corey V, Clarke D, Derbyshire ER, Dornan GL, Duffy S, Eckley S, Itoe MA, Koolen KM, Lewis TA, Lui PS, Lukens AK, Lund E, March S, Meibalan E, Meier BC, McPhail JA, Mitasev B, Moss EL, Sayes M, Van Gessel Y, Wawer MJ, Yoshinaga T, Zeeman AM, Avery VM, Bhatia SN, Burke JE, Catteruccia F, Clardy JC, Clemons PA, Dechering KJ, Duvall JR, Foley MA, Gusovsky F, Kocken CH, Marti M, Morningstar ML, Munoz B, Neafsey DE, Sharma A, Winzeler EA, Wirth DF, Scherer CA, Schreiber SL. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature. 2016 Oct 20;538(7625):344-349. doi: 10.1038/nature19804. Epub 2016 Sep 7. PMID: 27602946; PMCID: PMC5515376.

2015 Malaria Vaccine Phase1 Clinical Development Vaccine

Draper SJ, Angov E, Horii T, Miller LH, Srinivasan P, Theisen M, Biswas S. Recent advances in recombinant protein-based malaria vaccines. Vaccine. 2015 Dec 22;33(52):7433-43. doi: 10.1016/j.vaccine.2015.09.093. Epub 2015 Oct 11. PMID: 26458807; PMCID: PMC4687528.